Top Markets
#1 Purr Purr +56.55%
#2 Pons Pons +53.28%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 StonkBroker StonkBroker +30.71%
#5 Non-Playable Coin Non-Playable Coin +28.02%
#6 TENDIES TENDIES +26.79%
#7 Kinetiq Kinetiq +26.27%
#8 ApeX ApeX +25.71%
#9 Morpho Morpho +22.27%
#10 OriginTrail OriginTrail +21.30%
Coin of the day
Purr Purr
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Pozycja w akcjach #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Cena akcji
$7.12
Ostatnia synchronizacja: 2023-03-08
Kapitalizacja rynkowa
$117.03M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
GB
Handel F-star Therapeutics, Inc. (FSTX)

Kategoria

Healthcare
Zyski dla F-star Therapeutics, Inc. (FSTX)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych F-star Therapeutics, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy F-star Therapeutics, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH